PMID- 24291972
OWN - NLM
STAT- MEDLINE
DCOM- 20140919
LR  - 20190918
IS  - 1882-0654 (Electronic)
IS  - 0009-918X (Linking)
VI  - 53
IP  - 11
DP  - 2013
TI  - [Prognostic factors in Guillain-Barre syndrome].
PG  - 1315-8
AB  - The prognosis of Guillain-Barre syndrome (GBS) is not as good as might be 
      expected. Among GBS patients, 30% do not respond to intravenous immunoglobulin 
      therapy (IVIg) and 10% may worsen after initial treatment (treatment-related 
      fluctuation). Recent prospective trials show that 16% of GBS patients are unable 
      to walk independently a year after onset of the disease. The prognosis of GBS is 
      influenced by clinical, electrophysiological and biological factors, of which the 
      clinical factors are most important. The Erasmus GBS Respiratory Insufficiency 
      Score (EGRIS) and the modified EGOS (Erasmus GBS Outcome Score) are very useful 
      for prediction of mechanical ventilation or aided walking. A small increase in 
      serum IgG (delta IgG) two weeks after IVIg treatment is useful as a biological 
      prognostic marker that is significantly associated with slow recovery and aided 
      walking at 6 months. Use of these factors makes it possible to predict the 
      prognosis of GBS patients, and to identify patients with a poor prognosis in the 
      early phase of the disease and provide these patients with intensive treatment. 
      An accurate prediction of the level of disability is important for improvement of 
      the prognosis of GBS.
FAU - Kaida, Kenichi
AU  - Kaida K
AD  - Division of Neurology, Department of Internal Medicine, National Defense Medical 
      College.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Rinsho Shinkeigaku
JT  - Rinsho shinkeigaku = Clinical neurology
JID - 0417466
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Biomarkers/blood
MH  - Disability Evaluation
MH  - Disease Progression
MH  - Electrophysiological Phenomena
MH  - Forecasting
MH  - Guillain-Barre Syndrome/*diagnosis/physiopathology/*therapy
MH  - Immunoglobulin G/blood
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Prognosis
MH  - Recovery of Function
MH  - Respiration, Artificial
MH  - Respiratory Function Tests/methods
MH  - Time Factors
MH  - Walkers
MH  - Walking
EDAT- 2013/12/03 06:00
MHDA- 2014/09/23 06:00
CRDT- 2013/12/03 06:00
PHST- 2013/12/03 06:00 [entrez]
PHST- 2013/12/03 06:00 [pubmed]
PHST- 2014/09/23 06:00 [medline]
AID - DN/JST.JSTAGE/clinicalneurol/53.1315 [pii]
AID - 10.5692/clinicalneurol.53.1315 [doi]
PST - ppublish
SO  - Rinsho Shinkeigaku. 2013;53(11):1315-8. doi: 10.5692/clinicalneurol.53.1315.